Case Report: Safety and efficacy of blinatumomab in combination with donor lymphocyte infusion for the prophylaxis of relapse following allogeneic hematopoietic stem cell transplantation in a pediatric patient with acute lymphoblastic leukemia - Takeaways - MDSpire

Case Report: Safety and efficacy of blinatumomab in combination with donor lymphocyte infusion for the prophylaxis of relapse following allogeneic hematopoietic stem cell transplantation in a pediatric patient with acute lymphoblastic leukemia

  • By

  • Yi-Tong Li

  • Yu Li

  • Li-Na Wang

  • Li-Bin Huang

  • June 17, 2026

  • 0 min

Share

  • 1

    Acute lymphoblastic leukemia (ALL) is the most common malignant hematological disease in children, with high-risk cases having poor prognosis.

  • 2

    Allogeneic hematopoietic stem cell transplantation (HSCT) is a key treatment for refractory/relapsed ALL, improving long-term survival rates.

  • 3

    Blinatumomab combined with donor lymphocyte infusion (DLI) was administered to a child with high-risk ALL to prevent post-transplant relapse.

  • 4

    The child experienced grade 1 cytokine release syndrome during treatment but did not suffer from severe adverse reactions.

  • 5

    This case suggests that sequential blinatumomab plus prophylactic DLI may be well-tolerated and effective for relapse prevention after HSCT.

Original Source(s)

Case Report: Safety and efficacy of blinatumomab in combination with donor lymphocyte infusion for the prophylaxis of relapse following allogeneic hematopoietic stem cell transplantation in a pediatric patient with acute lymphoblastic leukemia

  • by Yi-Tong Li, Yu Li, Li-Na Wang, Li-Bin Huang

  • June 17, 2026

Related Content

Epstein–Barr virus-driven immunosuppression in nasopharyngeal carcinoma: a comprehensive review of viral mechanisms, spatial tumor ecosystems, and precision therapeutics

Expert consensus from the Chinese medical association on pharmaceutical management of combined cardio-oncology physician-pharmacist clinics

Tissue-Resident NK Cells Slow Solid Tumor Growth in Mice

The study points to a possible off-the-shelf cell therapy for solid tumors

  • June 16, 2026

  • 3 min